← Leaderboards
Luis N Brandao
University Of Colorado Denver
$167,826
Attributed
$167,826
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $58.7K · FY2009–11$100K$75K$50K$25K$0
'09
'10
'11
Funding mix
By agency
NIH$167,826 · 1
By mechanism
F32$167,826 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Rajesh Agarwal$27,337,251
- Terry J. Fry$3,169,598
- Paul A Bunn$21,859,370
- Christopher J Hogan$3,578,736
- Mamuka Kvaratskhelia$22,358,187
Others in their field
Top investigators on “Apoptotic”
- Douglas R Green · Burnham Institute For Medical Research$36,561,515
- Ira A Tabas · Columbia University Health Sciences$25,367,980
- Robert L Ferris · University Of Pittsburgh At Pittsburgh$21,268,306
- Anthony G Letai · Dana-Farber Cancer Inst$20,781,967
- Augustine M Choi · Weill Medical Coll Of Cornell Univ$19,019,183
- Loren D Walensky · Northeastern University$17,252,485
Research focus
ApoptoticBiologic DevelopmentB-LymphocytesBone Marrow CellsBone Marrow TransplantationCell LineCellsCessation Of LifeChemotherapyChildChildhoodClinically RelevantDown-RegulationEngraftmentHematopoieticHematopoietic Stem CellsInhibitor/AntagonistIn VitroIn VivoKineticsKnockout MiceLeukemiaLeukemia, Lymphocytic, AcuteAcute T Cell Leukemia
Grant awards (3)
MerTK contribution to leukemogenesis and validation as a therapeutic target$58,682
F32 · FY2011 · HL · contact PI
MerTK contribution to leukemogenesis and validation as a therapeutic target$55,790
F32 · FY2010 · HL · contact PI
MerTK contribution to leukemogenesis and validation as a therapeutic target$53,354
F32 · FY2009 · HL · contact PI